RELMADA THERAPEUTICS, INC.
No enriched coverage for $RLMD in the last 7 days.
No SEC Form 4 filings for $RLMD in the last 30 days.
Relmada Therapeutics announced strong 12-month Phase 2 data for NDV-01 in bladder cancer, with complete response rates up to 95% and durable responses up to 80% at 12 months. The company plans to launch its Phase 3 RESCUE program in mid-2026 and has secured $234 million in funding, ensuring operations through 2029 despite increased quarterly net losses. An analyst has rated RLMD stock as a Buy with a $19.00 price target.
Leerink Partners has upgraded Relmada Therapeutics (RLMD) from Market Perform to Outperform, with an average one-year price target of $10.20 per share, suggesting a 160.54% upside. Institutional ownership in RLMD increased by 49.27% in the last quarter, and the put/call ratio indicates a bullish outlook for the company.
Image source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
